We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+2.5%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$183M
AUM Growth
-$648M
Cap. Flow
-$649M
Cap. Flow %
-355.28%
Top 10 Hldgs %
95.28%
Holding
36
New
4
Increased
–
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$9.38M
2
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$3.63M
3
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$2.98M
4
SRZNW
Surrozen Inc Warrant
SRZNW
+$458K

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$155M
2
SWTX
SpringWorks Therapeutics
SWTX
+$68.8M
3
LEGN icon
Legend Biotech
LEGN
+$67.6M
4
VSTM icon
Verastem
VSTM
+$55.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$54.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
2 Financials 7.51%
3 Miscellaneous 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TKNO icon
26
Alpha Teknova
TKNO
$360M
– –
-75,000
Closed -$1.78M
TNGX icon
27
Tango Therapeutics
TNGX
$4.14B
– –
-180,000
Closed -$2.05M
VSTM icon
28
Verastem
VSTM
$680M
– –
-1,133,335
Closed -$55.4M
ARYD
29
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-250,000
Closed -$2.68M
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-388,222
Closed -$14.2M
GMDA
31
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-2,858,558
Closed -$18.3M
INFI
32
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-3,766,817
Closed -$11.3M
SIOX
33
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,969,987
Closed -$8.11M
CFMS
34
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-509,761
Closed -$14.7M
CHFW.U
35
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
– –
-1,000,000
Closed -$10.4M
CMAX
36
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
– –
-7,101
Closed -$2.75M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Consonance Capital Management held 36 positions worth $183M, down 78% from $831M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Consonance Capital Management withdrew a net $649M in Q3 2021, closing 19 positions and reducing 6 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $155M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 97% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, Consonance Capital Management opened a new position in Surrozen worth $6.72M.

  • Consonance Capital Management's largest Q3 2021 buy was Surrozen: 66,667 shares worth $6.72M.
  • Consonance Capital Management's biggest Q3 2021 reduction was SpringWorks Therapeutics, cutting an estimated $68.8M.
  • Consonance Capital Management fully exited Protagonist Therapeutics in Q3 2021, selling an estimated $155M.
  • Consonance Capital Management's ten largest holdings make up 95% of its $183M portfolio in Q3 2021.
  • Consonance Capital Management opened 4 new positions and closed 19 in Q3 2021.
  • Consonance Capital Management's portfolio value fell 78% quarter-over-quarter to $183M.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.